Results. Hypoxia during normothermia reduced gastric mHbO 2 by 27 (3)% and oral mHbO 2 by 28 (3)% (absolute change). During hypothermia, this reduction was attenuated to 16 (3)% and 13 (1)% (absolute change). This effect was independent of microvascular flow that did not change during hypoxia and hypothermia. Additional administration of levosimendan during hypothermia restored reduced cardiac output but did not change flow or mHbO 2 compared with hypothermia alone. Glibenclamide did not exert any additional effects during hypothermia.
Conclusions. Hypothermia attenuates the decrease in mHbO 2 during additional hypoxic challenges independent of systemic or regional flow changes. A reduction in cardiac output during hypothermia is prevented by Ca 2+ sensitization with levosimendan but not by K + ATP channel blockade with glibenclamide.
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Hypoxia complicates critical care settings. It occurs during pulmonary complications such as acute respiratory distress syndrome (ARDS) and medical interventions 1 2 but also during cardiopulmonary resuscitation and cardiopulmonary bypass. In this context, the gastrointestinal tract seems extremely susceptible to hypoxia. Under physiological conditions, it functions as an effective barrier against endotoxins and bacteria, and perfusion of the mucosa is vital to maintain this barrier function. 3 -5 Insufficient microcirculatory oxygen supply leads to such as neonatal asphyxia, trauma, carbon monoxide intoxication, and anaemia 13 14 on tissues such as the brain, spinal cord, liver, and heart. 13 15 16 We have recently shown that hypothermia improves oral and gastric mucosal oxygenation (sites known to reflect microcirculation of other gastrointestinal regions) 17 18 during haemorrhage. 19 Thus, hypothermia might improve oxygenation of the same tissues during hypoxia as well. The aim of this study was to evaluate the effect of mild hypothermia on oral and gastric mucosal oxygenation during hypoxia. However, hypothermia is associated with a variety of negative effects like suppression of the immune system, an impaired coagulation cascade, and a mild reduction in cardiac output 13 20 that might conversely reduce oxygen supply to tissues. Additionally, hypoxia itself also depresses cardiac function by myofilament Ca 2+ desensitization 21 and by vasodilation via activation of K + ATP channels. 22 23 To counteract these effects, the Ca 2+ sensitizer levosimendan and the K + ATP channel blocker glibenclamide might be attractive options to support the cardiovascular system and thereby improve gastrointestinal oxygenation. Ca 2+ sensitization with levosimendan has been shown to improve cardiac function during hypoxia 24 and gastric oxygenation during normothermia. 25 K + ATP channel blockade might prevent vasodilation and is of growing interest in intensive care medicine. 26 Inhibitors of K + ATP channels such as glibenclamide are studied as non-adrenergic vasopressors known to increase systemic vascular resistance (SVR). 26 27 In this study, we tested the effects of levosimendan (to improve cardiac contractility) and glibenclamide (to increase SVR) during compromised cardiac output under first hypothermia and second hypothermia during hypoxia and evaluated the role of vasoactive K + ATP channels in the protection of gastrointestinal microcirculation.
Taken together, the aim of our study was to answer the following questions:
(i) Does mild hypothermia improve oral and gastric mucosal oxygenation during additional hypoxic challenges? (ii) Does calcium sensitization with levosimendan or K + ATP channel blockade with glibenclamide support the cardiovascular system and the microcirculation during hypothermia and hypothermia under hypoxia? (iii) Which role do vasoactive K + ATP channels play in the protection of gastrointestinal microcirculation during hypothermia and hypoxia?
Methods

Animals
The data were derived from repetitive experiments on five dogs [female foxhounds, weighing 28 (1) kg] treated in accordance with NIH guidelines for animal care. Larger animals were studied because of the requirement of repeated measurements of haemodynamic variables and blood gas analyses. Experiments were performed with approval of the local animal care and use committee (North Rhine-Westphalia State Agency for Nature, Environment and Consumer Protection, Recklinghausen, Germany; ref. 87-51.04.2010.A073).
Before the experiments, food was withheld overnight with water ad libitum to ensure complete gastric depletion and to avoid changes in perfusion and oxygenation due to digestive activity. This study was performed as a cross-over study, so that each dog underwent each experimental protocol in a randomized order and served as its own control. Experiments were performed at least 3 weeks apart to prevent carryover effects. The experiments were performed under general anaesthesia (induction of anaesthesia with 4 mg kg 21 propofol, maintenance with sevoflurane, end-tidal concentration 3.0%, 1.5 MAC in dogs). BIS monitoring was used to ascertain adequate depth of anaesthesia. The animals were mechanically ventilated after tracheal intubation (FI O 2 =0.3; VT¼12.5 mg kg
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, a normal tidal volume for dogs) 28 with the respiratory frequency adjusted to achieve normocapnia (end-expiratory carbon dioxide E ′ CO 2 =4.7 kPa), verified by continuous capnography (Capnomac Ultima, Datex Instrumentarium, Helsinki, Finland). During baseline conditions, the dogs were placed on their right side and covered with warming blankets to maintain body temperature at 37.58C (continuous arterial measurement). Throughout the experiments, no additional fluid replacement was administered to avoid volume effects that could influence tissue perfusion and oxygenation. However, after withdrawal of each blood sample, normal saline was infused three times the sampling volume to maintain blood volume. After each experiment, and complete re-warming, inhalation of sevoflurane was stopped. The extubation was performed after re-establishing spontaneous breathing. The animals were observed until full recovery from anaesthesia.
Measurements
Systemic haemodynamic and oxygenation variables
The aorta was catheterized via the left carotid artery for continuous measurement of mean arterial pressure (MAP, GouldStatham pressure transducers P23ID, Elk Grove, IL, USA) and intermittent arterial blood gas samples (Rapidlab 860, Bayer AG, Germany). Oxygen saturation was calculated for canine blood from PO 2 and adjusted to pH and temperature. 29 Arterial oxygen content (CaO 2 ) and systemic oxygen delivery (systemic DO 2 ¼CaO 2 ×cardiac output) were calculated subsequently. Cardiac output was determined via transpulmonary thermodilution (PiCCO 4.2 non-US, PULSION Medical Systems, Munich, Germany) at the end of each intervention, at least every 30 min, as previously described. 30 Heart rate (HR) was continuously measured by electrocardiography (Powerlab, ADInstruments, Castle Hill, Australia). All haemodynamic and respiratory variables were recorded on a personal computer after analogue to digital conversion (Powerlab, ADInstruments) for later analysis.
Mucosal oxygenation and perfusion
Microvascular oxygen saturation (mHbO 2 ) and microvascular flow (mflow) of the gastric and oral mucosa were continuously assessed by tissue reflectance spectrophotometry and laser Doppler flowmetry, respectively (O2C, LEA Medizintechnik, Gießen, Germany), as detailed previously. 30 White light (450 -1000 nm) and laser light (820 nm, 30 mW) are transmitted to the tissue of interest via a micro-lightguide and the reflected light is analysed. The wavelength-dependent absorption and overall absorption of the applied white light can be used to calculate the percentage of oxygenated haemoglobin (mHbO 2 ) and the amount of haemoglobin (mHb). Owing to the Doppler effect, the magnitude and frequency distribution of changes in wavelength are proportional to the number of blood cells multiplied by the measured mean velocity of these cells. This product is proportional to flow and expressed in arbitrary perfusion units (aU). Hence, this method allows assessment and comparison of oxygenation and perfusion of the same region at the same time. Changes of flow can be attributed either to change of velocity or the number of red blood cells, comparable with the information gained by intravital microscopy.
Since light is totally absorbed in vessels with a diameter .100 mm, 31 only microvascular oxygenation of nutritive vessels of the mucosa is measured. The biggest fraction of the blood volume is stored in venous vessels; therefore, mainly postcapillary oxygenation is measured which represents the critical partial pressure of oxygen (PO 2 ) for ischaemia.
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One flexible lightguide probe is placed in the mouth facing the buccal side of the oral mucosa and a second probe is introduced into the stomach via an orogastric silicone tube and positioned facing the greater curvature. 33 Both sites of measurement represent the microcirculation of other gastrointestinal mucosa regions. 17 18 Online evaluation of the signal quality throughout the experiments allows verification of the correct position of the probe tip. The mHbO 2 and mflow values reported are the means of the last 5 min (150 spectra, 2 s each) of the respective intervention under steady-state conditions. The non-traumatic instrumentation and in particular non-traumatic access to the gastric mucosa allows the determination of mucosal microcirculation in the absence of surgical stress. This is particularly desirable with respect to the marked alterations that surgical stress exerts on splanchnic circulation. 34 In this situation, reflectance spectrophotometry reliably detects even clinically asymptomatic reductions in mucosal oxygenation 35 and highly correlates with the morphological severity and extent of gastric mucosal tissue injury. 36 Regional mucosal oxygen delivery (mDO 2 ) was calculated from mucosal blood flow and arterial oxygen content (mDO 2 ¼ CaO 2 ×regional flow). Mucosal oxygen consumption (VO 2 ) was calculated from the difference in arterio-postcapillary oxygen content (DC av O 2 ) and regional flow (VO 2 ¼C av O 2 ×regional flow). Since flow signals of the gastric probe did not have sufficient quality in some experiments, only flow signals of the oral mucosa are presented.
Induction of hypothermia
Body temperature was reduced continuously over 90 min to achieve a core temperature of 348C. Four commercially available cooling packs (Gello GmbH, Ahaus, Germany) were wrapped into towels and placed around the paws while crushed ice stored in bags was wrapped into towels and placed on the body. Body temperature was continuously measured via arterial catheter (PiCCO 4.2). When temperature decreased below 348C, forced-air warming (Bair Hugger, Model 500, Augustine Medical, Inc., Eden Prairie, MN, USA) at 388C was used to maintain the body temperature at 348C. At the end of the experiment, normal body temperature for dogs (37-38.58C) was restored using forced-air warming. 
Induction of hypoxia
Hypoxia was induced by reducing inspiratory oxygen concentration from 30% to 12% for 15 min.
Experimental programme
Following the instrumentation, 30 min was allowed to establish steady-state conditions and baseline values were recorded before the animals were randomized to the respective protocol (Fig. 1) . The randomization was achieved using a manual random chart.
Hypothermia+hypoxia (HT/HPX)
To study the effects of additional hypoxia during hypothermia on mHbO 2 , body temperature was reduced over 90 min. Hypothermia was maintained subsequently and all variables were recorded. After 60 min of hypothermia, hypoxia was induced as described. After the observation period, normal body temperature was restored over 120 min.
Control experiment, hypoxia (HPX)
As time control experiment, hypoxia was induced at the same time point as above during normothermia.
Hypothermia+hypoxia+glibenclamide (HT/Glib/HPX)
To study the effect of glibenclamide as K + ATP channel antagonist, hypothermia was induced as described above. During hypothermia, glibenclamide (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) was infused over 10 min (0.2 mg kg 21 ) and further 20 min was allowed for stabilization. Hypoxia was induced as described above, followed by re-warming.
Hypothermia+hypoxia+levosimendan (HT/Levo/HPX)
To study the effect of levosimendan, hypothermia was induced as described above. During hypothermia, 20 mg kg 21 levosimendan (Simdax, Orion Corp., Espoo, Finland) was infused over 15 min, followed by infusion of 0.25 mg kg min 21 and a further 15 min was allowed for stabilization. Hypoxia was induced as described above, followed by re-warming.
At the end of each intervention, blood samples were obtained for blood gas analysis.
Statistical analysis
Data for analysis were obtained during the last 5 min of each intervention under steady-state conditions. Normal data distribution was assessed in Q-Q plots (IBM SPSS Statistics, International Business Machine Corp., USA). All data are presented as absolute values of mean (standard error) [mean (SEM)] for n¼5 animals. Differences within the groups and between the groups were tested using an analysis of variance for repeated measurements and a Fisher's PLSD test as post hoc test (StatView V4.1, SAS Institute, Inc., Cary, NC, USA), P,0.05 was considered significant.
Results
Effects during normothermia
During normothermia, a short hypoxic period reduced gastric mHbO 2 by 27 (3)% and oral mHbO 2 by 28 (3)% (Fig. 2) . Additionally, it reduced systemic oxygen delivery from 15 (2) to 11 (1) (Fig. 3 , Table 2 ).
Effects during hypothermia
Hypothermia alone (2.5 h) had no effect on gastric mHbO 2 . However, hypothermia increased oral mHbO 2 in all three hypothermic groups [from 78 (2)% to 81 (1)% in Group HT/HPX, from 77 (2)% to 81 (3)% in Group HT/Glib/HPX, and from 77 (1)% to 84 (2)% in Group HT/Levo/HPX] ( Table 2 ). The reduction in oral and gastric mHbO 2 , caused by a short period of hypoxia, was significantly attenuated during hypothermia to a decrease of 16 (3)% (gastric) and 13 (1)% (oral mHbO 2 ) and not influenced additionally by glibenclamide [12 (3)% vs 18 (2)%] or levosimendan [16 (3)% vs 17 (2)%] (Fig. 2) .
This improvement of mHbO 2 was independent of changes in DO 2 which decreased from 13 (2) to 10 (1) ml kg 21 min
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( Table 2) . During hypothermia, systemic oxygen delivery decreased due to both reduction in oxygen partial pressure from 21.7 (0.3) to 5.9 (0.4) kPa and reduction in cardiac output from 84 (9) to 73 (4) ml kg 21 min 21 (Fig. 3 , Table 2 ).
This reduced cardiac output is mainly related to a reduction in HR from 108 (6) to 88 (3) beats min 21 (Table 2) . Levosimendan, however, was able to restore cardiac output from 80 (4) to 88 (4) (Fig. 3) , and reduced SVR from 28 (2) to 24 (2) mm Hg min litre 21 . (2) 13 (1) 13 (1) 9 (1)* HT/Levo/HPX 14 (1) 14 (1) 15 (1) Glibenclamide did not change cardiac output and failed to modify SVR (Fig. 3 , Table 2 ).
Regional perfusion
In contrast to the effect of hypothermia on oxygenation, perfusion under hypoxia neither changed during normothermia [from 136 (29) to 128 (31) aU] nor during hypothermia [from 149 (33) to 148 (37) aU] (Fig. 4 , Table 2 ). Regional mucosal oxygen delivery did not change subsequently. In contrast, mucosal oxygen consumption seemed reduced during hypoxia, but this change failed to reach statistical significance (Fig. 4) .
Discussion
Based on our data, our findings are the following:
(i) Mild hypothermia attenuates the decrease in oral and gastric mucosal oxygenation during additional hypoxic challenges. (ii) Calcium desensitization seems to account for reduced cardiac output during hypothermia and additional hypoxia which can be restored by levosimendan in dogs. However, this effect appears not to modify regional oxygenation or perfusion during hypothermia. Hypothermia is known to reduce tissue injury after periods of hypoxia. Additionally, during hypothermia, further hypoxic challenges are known to have only minor impact on organ function. In this context, we have recently shown in an animal study that hypothermia attenuates the effects of haemorrhage on perfusion and thus improves oral and gastric mucosal oxygenation during haemorrhagic shock. 19 In the present study, we aimed to analyse whether hypothermia likewise attenuates the decrease in mHbO 2 during hypoxic challenges. However, hypothermia and hypoxia might both reduce cardiac output to a minor extent with possible additive effects on microcirculation. This effect is partially mediated by myofilament Ca 2+ desensitization and vasodilation via activation of K + ATP channels. 21 -23 Thus, we evaluated the potential role of the myofilament Ca 2+ sensitizer levosimendan and K + ATP channel blocker glibenclamide to support the cardiovascular system during hypothermia and hypoxia and evaluated the role of vasoactive K + ATP channels on microcirculation. It is one limitation of the study that the data are derived from an animal study on five dogs, and therefore, their impact on humans has to be interpreted with care.
In this study, hypoxia strongly reduced both oral and gastric mHbO 2 which was attenuated during hypothermia at 348C. This effect was independent of systemic and regional oxygen delivery that does not differ between normothermia and hypothermia, despite differences in cardiac output. Hence, this might rather be related to the shift of the oxygen-haemoglobin dissociation curve to the left during hypothermia, leading to a higher oxygen saturation at a given oxygen partial pressure. This could lead to insufficient oxygen supply to tissues. However, this seems not to be the case in this study since plasma lactate levels remained unchanged throughout the experiments. One explanation might be a reduced metabolism and thus reduced oxygen demand, which could be observed only in the oral mucosa and is supported by oral VO 2 that seemed to decrease, although it failed to reach significance. However, this could not be observed in the gastric mucosa where hypothermia alone had no effect on mHbO 2 .
Thus, it is interesting that regional oxygenation is improved while regional perfusion remains unchanged in this animal study. Although this is not completely surprising, it indicates that there is no strict relationship between perfusion and oxygenation. Measurement of perfusion solely seems to be not reliable enough to assess microcirculation. Although it seems obvious that measurement of oxygen saturation is more reliable to detect ischaemia, parallel assessment of oxygenation and perfusion seems to be more accurate to evaluate microcirculation. We have recently shown that hypothermia attenuated the decrease in microcirculatory perfusion and thus oxygenation. Hence, hypothermia seems to have effects on perfusion and exerts vasodilatory effects. Vasodilatory effects of hypothermia seem unexpected but have been observed in cerebral vessels as well. 37 In the present study, however, mHbO 2 increased independent of flow and vasodilatory effects could not be observed.
Neither the reduced cardiac output during hypothermia nor the restored flow during levosimendan infusion seem to affect splanchnic microcirculation, although levosimendan increased mHbO 2 and cardiac output during normothermia in previous studies. 25 The effect of additional hypoxia during hypothermia on mHbO 2 seems completely independent of systemic variables in this study. Even systemic oxygen delivery-with highest levels during levosimendan infusion-does not seem to affect regional oxygenation additionally compared with hypothermia alone. Thus, during hypothermia, negative effects of additional hypoxia on splanchnic oxygenation might be attenuated independent of systemic variables. Although hypoxia is known to reduce cardiac function, 21 this
was not observed in our experiments. This might be related to the short period of hypoxia. However, we observed a mild decrease in cardiac output related to hypothermia (consistent with clinical observations) 20 that was restored by levosimendan. The increase in cardiac output by levosimendan in dogs seems to be comparable with its effect during normothermia, where it is achieved without increasing oxygen consumption. 24 While a variety of studies indicate that levosimendan supports cardiac function during heart failure, studies on the effect of levosimendan during hypothermia are rare. One study observed inotropic effects of levosimendan under hypothermia in isolated hearts. 38 Another study observed inotropic and lusitropic effects of levosimendan after cardioplegic arrest only during normothermia but not during hypothermia; however, this study was also conducted in isolated hearts as well. 39 Thus, we could demonstrate that levosimendan might be an option to improve cardiac output during mild hypothermia. However, these results obtained in an animal study have to be confirmed in clinical studies. The observed positive effects of levosimendan on microcirculation during normothermia in a similar animal model 25 could not be observed during hypothermia in our study. In this experimental study, K + ATP channel blockade, in contrast to calcium sensitization, did not affect the cardiovascular system. Glibenclamide neither increased SVR under hypothermia nor under additional hypoxia. MAP did not change and cardiac output remained low. Studies in isolated hearts and myocardial cells suggest temperature-dependent inhibition of K + ATP channels. 40 41 The absence of any effects on SVR in our model suggests that hypothermia inhibits K + ATP channels in vivo as well. Thus, despite promising reports on glibenclamide as vasopressor, 26 27 according to our results, its effects might not become visible during therapeutic hypothermia. Additionally, K + ATP channel blockade with glibenclamide did not change mHbO 2 compared with hypothermia alone. Thus, K + ATP channels do not seem to be involved in vasoregulation of the oral and gastric mucosa during hypoxia under hypothermia. This might be due to inhibition of these channels during hypothermia, 40 41 making pharmacological interventions impossible.
In this standardized animal model, the measured parameters are very constant during baseline conditions, resulting in a very small SEMs. Thus, even small changes might be significant, although possibly not clinically relevant. We presented only data in the Results section that seem clinically relevant to us. The complementary data in the table are for the sake of completeness. However, whether changes are clinically relevant depends on the circumstances (healthy vs ill patients, additional compromising conditions) and cannot be answered in general.
Limitations of this study
This is an animal study with n¼5 dogs. The number of animals seems to be rather small since we are forced by law to minimize animal experiments. However, the use of a cross-over design where each animal serves as its own control and eliminates inter-individual differences allows using a rather small number of animals. However, we did not correct for multiple comparisons. This increases the power to detect differences with small sample sizes and the power of this study was high enough to detect significant changes. Correcting for multiple comparisons requires a large amount of dogs or reduces the power to detect effects (increasing type II error). This, in contrast, includes an increased chance for type I errors. Thus, the implication of our results has to be interpreted with care and the results of this animal study have to be analysed in a clinical setting in the future.
Conclusions
Hypothermia attenuates the decrease in oral and gastric mucosal microcirculatory oxygenation during additional hypoxic challenges in dogs. In this study, calcium sensitization with levosimendan but not K + ATP channel blockade with glibenclamide restored cardiac output during hypothermia and additional hypoxia. However, effects of levosimendan on gastrointestinal microcirculation seem to be abolished during hypothermia. Vasoactive K + ATP channels do not seem to play any role in the protection of gastrointestinal microcirculation in this experimental study during hypothermia and hypoxia.
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